期刊
CHINESE MEDICAL JOURNAL
卷 129, 期 17, 页码 2026-2032出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.4103/0366-6999.189052
关键词
Macrophage Inhibitory Cytokine-1; Nonsmall Cell Lung Cancer; Sensitivity; Specificity
资金
- National Natural Science Foundation of China [81502023, 81441080]
- National High-tech R&D Program (863 Program) [2008AA02Z415]
- Capital Characteristic clinic projects [Z12110700102066]
Background: Increased level of serum macrophage inhibitory cytokine-1 ( MIC-1), a member of transforming growth factor-beta superfamily, was found in patients with epithelial tumors. This study aimed to evaluate whether serum level of MIC-1 can be a candidate diagnostic and prognostic indicator for early-stage nonsmall cell lung cancer (NSCLC). Methods: A prospective study enrolled 152 patients with Stage I-II NSCLC, who were followed up after surgical resection. Forty-eight patients with benign pulmonary disease (BPD) and 105 healthy controls were also included in the study. Serum MIC-1 levels were measured using an enzyme-linked immunosorbent assay, and the association with clinical and prognostic features was analyzed. Results: In patients with NSCLC, serum protein levels of MIC-1 were significantly increased compared with healthy controls and BPD patients (all P<0.001). A threshold of 1000 pg/ml of MIC-1 was found in patients with early-stage (Stage I and II) NSCLC, with sensitivity and specificity of 70.4% and 99.0%, respectively. The serum levels of MIC-1 were associated with age (P=0.001), gender (P=0.030), and T stage (P=0.022). Serum MIC-1 threshold of 1465 pg/ml was found in patients with poor early outcome, with sensitivity and specificity of 72.2% and 66.1%, respectively. The overall 3-year survival rate of NSCLC patients with high serum levels of MIC-1 (>= 1465 pg/ ml) was lower than that of NSCLC patients with low serum MIC-1 levels (77.6% vs. 94.8%). Multivariate Cox regression survival analysis showed that a high serum level of MIC-1 was an independent risk factor for reduced overall survival (hazard ratio = 3.37, 95% confidential interval: 1.09-10.42, P=0.035). Conclusion: The present study suggested that serum MIC-1 may be a potential diagnostic and prognostic biomarker for patients with early-stage NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据